SEARCH

SEARCH BY CITATION

References

  • 1
    Whyte IM. Serotonin toxicity (Syndrome). In: DartRC, ed. Medical Toxicology. Baltimore: Lippincott, Williams & Wilkins, 2004: 1036.
  • 2
    Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of Toxicology Clinical Toxicology 2004; 42: 27785.
  • 3
    Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Quarterly Journal of Medicine 2003; 96: 36974.
  • 4
    Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. Hunter serotonin toxicity criteria: a simple and accurate diagnostic decision rule for serotonin toxicity. Quarterly Journal of Medicine 2003; 96: 63542.
  • 5
    Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biology Psychiatry 2006: in press.
  • 6
    Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia 2005; 95: 43441.
  • 7
    Gillman PK. The serotonin syndrome and its treatment. Journal of Psychopharmacology 1999; 13: 1009.
  • 8
    Gillman PK. Serotonin syndrome: history and risk. Fundamental and Clinical Pharmacology 1998; 12: 48291.
  • 9
    Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochemistry International 2003; 43: 15564.
  • 10
    Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT) (2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5–HT syndrome. Brain Research 2001; 890: 2331.
  • 11
    Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacology, Biochemistry and Behavior 2002; 71: 83744.
  • 12
    Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995; 45: 21923.
  • 13
    Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine 2005; 352: 111220.
  • 14
    Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. Journal of Clinical Psychiatry 2004; 65: 15204.
  • 15
    Vuori E, Henry JA, Ojanpera I, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003; 98: 3658.
  • 16
    Mechan AO, Esteban B, O'Shea E, et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. British Journal of Pharmacology 2002; 135: 17080.
  • 17
    Buckley NA, Whyte IM, Dawson AH. Diagnostic data in clinical toxicology – should we use a Bayesian approach? Journal of Toxicology Clinical Toxicology 2002; 40: 21322.
  • 18
    Gill CJ, Sabin L, Schmid CH. Why clinicians are natural Bayesians. British Medical Journal 2005; 330: 10803.
  • 19
    Isbister GK, Downes F, Whyte IM. Olanzapine and serotonin toxicity. Psychiatry and Clinical Neurosciences 2003; 57: 2412.
  • 20
    Whyte IM, Isbister GK. Misdiagnosis of myoclonus in antidepressant induced serotonin excess. Veterinary and Human Toxicology 2001; 43: 3756.
  • 21
    Isbister GK, Dawson AH, Whyte IM. Comment: neuroleptic malignant syndrome associated with risperidone and fluvoxamine. Annals of Pharmacotherapy 2002; 36: 1294.
  • 22
    Isbister GK, Whyte IM. Atypical presentation of risperidone toxicity. Veterinary and Human Toxicology 2002; 44: 1189.
  • 23
    Isbister GK, Whyte IM, Smith AJ. Olanzapine overdose. Anaesthesia 2001; 56: 4001.
  • 24
    Gillman PK. NMS and ST: chalk and cheese. British Medical Journal 2005 http://bmj.bmjjournals.com/cgi/eletters/329/7478/1333.
  • 25
    Gillman PK. Understanding toxidromes: serotonin toxicity. A commentary on Montanes-Rada et al. Journal of Clinical Psychopharmacology 2005; 25: 6256.
  • 26
    Gillman PK. Making sense of serotonin toxicity reports, a comment on Chopra et al. (World J Biol Psychiatry 2004; 5: 114–5). World Journal of Biological Psychiatry 2004; 5: 1678.
  • 27
    Gillman PK. The spectrum concept of serotonin toxicity. Pain Medicine 2004; 5: 2312.
  • 28
    Gillman PK. Mirtazapine: unable to induce serotonin toxicity? Clinical Neuropharmacology 2003; 26: 2889.
  • 29
    Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Human Psychopharmacology 2006; 21: 11725.
  • 30
    Otte W, Birkenhager TK, Van Den Broek WW. Fatal interaction between tranylcypromine and imipramine. European Psychiatry 2003; 18: 2645.
  • 31
    Smith RL. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine 2005; 2: e138.
  • 32
    Horton R. The dawn of McScience. New York Review of Books 2004; 51: 79.
  • 33
    Angell M. The Truth About Drug Companies: How They Deceive Us and What to Do About It. New York: Random House, 2005: 336.
  • 34
    Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996; 347: 10246.
  • 35
    Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. British Medical Journal 1997; 315: 63540.
  • 36
    Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 9218.
  • 37
    Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 245765.
  • 38
    Parker G, Anderson IM, Haddad P. Clinical trials of antidepressant medications are producing meaningless results. British Journal of Psychiatry 2003; 183: 1024.
  • 39
    Grimes DA, Schulz KF. Descriptive studies: what they can and cannot do. Lancet 2002; 359: 1459.
  • 40
    Procopio M. Publication of case reports. British Journal of Psychiatry 2005; 187: 91.
  • 41
    David TJ. Should the JRSM publish more case reports? Discussion paper. Journal of the Royal Society of Medicine 1986; 79: 5413.
  • 42
    Martyn C. Case reports, case series and systematic reviews. Quarterly Journal of Medicine 2002; 95: 1978.
  • 43
    Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960; 10: 10768.
  • 44
    Insel T, Roy B, Cohen R, Murphy D. Possible development of the serotonin syndrome in man. American Journal of Psychiatry 1982; 139: 9545.
  • 45
    Sorinola O, Olufowobi O, Coomarasamy A, Khan KS. Instructions to authors for case reporting are limited: a review of a core journal list. BMC Medical Education 2004; 4: 4.
  • 46
    Godlee F. Applying research evidence to individual patients. Evidence based case reports will help. British Medical Journal 1998; 316: 16212.
  • 47
    Haddow AM, Harris D, Wilson M, Logie H. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. British Medical Journal 2004; 329: 13335.
  • 48
    Michell B. Editors are meant to be judges, not postmen. Nature 2003; 423: 47980.